Member access

4-Traders Homepage  >  Shares  >  Toronto Stock Exchange  >  Cardiome Pharma Corp.    COM   CA14159U3010

News SummaryMost relevantAll newsSector news 

CARD PHARM : Cardiome to Hold Conference Call to Discuss First Quarter Results and Corporate Update

07/25/2011 | 05:56pm US/Eastern

Vancouver, Canada, July 25th, 2011 ? Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced it will hold a conference call to discuss Q1-2011 financial results and to provide a corporate update.

To access the conference call, please dial 416-340-2217 or 866-696-5910 and reference conference 6435784 . There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome?s website at .

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through August 26th, 2011. Please dial 905-694-9451 or 800-408-3053 and enter code 7372760# to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at

For Further Information:  

Cardiome Investor Relations  (604) 676-6993 or Toll Free: 1-800-330-9928 Email:

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words ?believe?, ?may?, ?plan?, ?will?, ?estimate?, ?continue?, ?anticipate?, ?intend?, ?expect? and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at and the Canadian securities regulatory authorities at Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

React to this article
2014 CARDIOME PHARMA : Enters Development And Commercialization Agreement With Edding..
2014 CARDIOME PHARMA : Enters Development and Commercialization Agreement with Edding..
2014 CARDIOME PHARMA : Enters Commercialization Agreement With Aspen For Brinavess In..
2014 CARDIOME PHARMA : Enters Commercialization Agreement with Aspen for BRINAVESS® i..
2014 CARDIOME PHARMA : Submits BRINAVESS® Reimbursement Dossier to Italian Authoritie..
2014 CARDIOME PHARMA : Reports Third Quarter 2014 Financial Results
2014 CARDIOME PHARMA : Announces Positive Results from the BRINAVESS® Asia-Pacific Ph..
2014 CARDIOME PHARMA : to Hold Third Quarter 2014 Financial Results Conference Call o..
2014 CARDIOME PHARMA : Enters Commercialization Agreement With Eurolab Especialidades..
2014 CARDIOME PHARMA : Enters Commercialization Agreement With Eurolab Especialidades..
Duration : Period :
Cardiome Pharma Corp. Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes